O

Otsuka Pharmaceutical

Global pharma maker of Abilify

Pharmaceutical Sales - Neuroscience Hospital Specialist

Full-Time
$116k - $166.8k/yr+ Incentive opportunity
Mid
Bakersfield, CA, USA
RemoteMust reside within 50 miles of Bakersfield; field travel by car may reach 70% of the time.
Sales & Account ManagementField Sales

About the job

Requirements
  • At least 2 years of pharmaceutical or medical device sales experience.
  • At least 4 years of sales experience working with healthcare professionals, ideally representing multiple products.
  • Must reside within a commutable distance of 50 miles from the primary city in the sales territory.
  • Must be able to travel in the field by car for up to 70% of the time, depending on the size of the ecosystem.
Responsibilities
  • Conduct proactive outreach to healthcare professionals on product access, on-label information, and established patient care guidance.
  • Engage customers through virtual and digital tools and direct them to other colleagues, such as Medical Science Liaisons, as needed.
  • Facilitate speaker programs and organize local provider groups for discussions on experiences and outcomes with local or regional leaders.
  • Elevate opportunities and feedback to the Area Business Lead, including local market insights to inform local strategy and business goals.
  • Use competitive data and business reports, including sales data and promotional budgets, to track progress and identify opportunities.
  • Apply knowledge of territory and business conditions affecting sales results to establish near-term territory business-plan priorities.
  • Respond compliantly to competitive threats and opportunities.
  • Educate office staff on payer guidelines and reimbursement procedures to increase pull-through.
  • Effectively use promotional materials.
  • Maintain awareness of internal support-team resources throughout the ecosystem and use them appropriately.
  • Apply market and industry knowledge to overcome objections and influence prescribing habits during the total office call.
  • Identify territory professional groups for networking and exposure to potential key opinion leaders.
  • Build relationships with key office and practice personnel, focus on patient health in conversations, take responsibility for follow-through, and provide accurate information in response to account needs.
  • Deliver effective and balanced office calls and sales presentations using approved marketing materials and technical references, including studies and package inserts, to help healthcare professionals enhance patient outcomes.
  • Demonstrate competent knowledge of the company’s products and competing products.
Desired Qualifications
  • Previous cross-functional industry experience in commercial life sciences or a related industry.
  • Central nervous system experience is highly valued.
  • Ability to work in an ambiguous environment undergoing transformation.
  • Proven track record in coaching, training, and mentoring peers or others.
  • Commitment to ethical business practices, understanding of regulatory standards, and ability to execute business activities in compliance with company policies and guidance.
  • Ability to assimilate and communicate complex clinical and product information.

About the company

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VOYXACT's August 2026 two-year data supports a supplemental FDA approval filing.
  • Transcend acquisition closed June 15, 2026, adding a differentiated neuropsychiatry pipeline.
  • Paradise renal denervation gained Japan insurance coverage March 1, 2026, accelerating sales.

What critics are saying

  • Abilify patents keep expiring through 2027, pressuring a legacy revenue engine.
  • Otsuka v Sun Pharma in Australia threatens ABILIFY MAINTENA patent-extension protection.
  • Transcend's PTSD asset, TSND-201, reaches Phase 3 completion only in late 2027.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs pharmaceuticals, devices, and diagnostics across renal, psychiatric, and cardiovascular care.
  • SIMTRIYO, approved July 23, 2026, is the first approved NDSRI for ADHD.
  • VOYXACT delivered 24-month eGFR stabilization, strengthening Otsuka's IgA nephropathy leadership.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Otsuka US
Sep 20th, 2026
Otsuka Completes Acquisition of Transcend Therapeutics to Advance Next-Generation Neuropsychiatric Treatments | Otsuka US

Otsuka America, Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. has completed the acquisition of Transcend Therapeutics, Inc., a clinical-stage biotechnology company developing a rapid-acting treatment for post-traumatic stress disorder (PTSD). This is the latest in a series of investments Otsuka has made to advance next-generation treatments for serious neuropsychiatric conditions.

Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.